Table 1.
Exp. No |
derivation protocol | Names of ESC lines used in study |
genetic background |
Oocytes activated |
number of blastocysts |
ESC lines obtained |
ESC lines with haploid contribution (max. % haploid before sorting) |
---|---|---|---|---|---|---|---|
1 | 2i / immunosurgery | HAP-1 to 6 † | B6CBAF1 | 132 | 30 | 27 | 6 (>60%) |
2 | 2i | HAP-7 | B6CBAF1 | 22 | 10 | 5 | 1 (>15%) |
3 | 2i | HTG-1 to 3 ‡ | mixed TG* | 50 | 32 | 3 | 3 (>90%) |
4 | KSR / immunosurgery | HAP-8 to 13 | B6CBAF1 | 273 | 48 | 22 | 6 (>10%) |
5 | 2i | H129B6-1 to 5 |
129B6F1 | 250 | 37 | 8 | 5 (>10%) 5 |
6 | 2i | HTX-1 | mixed TG** | 70 | 11 | 1 | 1 (>40%) |
7 | 2i | H129-1 to 3 | 129Sv | 140 | 13 | 10 | 3 (>60%) |
Contribution to chimeric mice was confirmed for the HAP-1 and HAP-2 haploid ESC lines.
Contribution to chimeric mice was confirmed for the HTG-1 haploid ESC line.
Derived from ROSA26nlsrtTA LC1 Xist2LOX homozygous female mice.
Derived from ROSA26nlsrtTA tetOPXist homozygous female mice30.